Cart
sales@molnova.com
Telocinobufagin
CAS No. 472-26-4
Telocinobufagin( Telobufotoxin | Telocinobufogenin )
Catalog No. M18585 CAS No. 472-26-4
Telocinobufagin is the major endogenous digitalis-like factor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 140 | In Stock |
|
| 5MG | 125 | In Stock |
|
| 10MG | 200 | In Stock |
|
| 25MG | 356 | In Stock |
|
| 50MG | 512 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTelocinobufagin
-
NoteResearch use only, not for human use.
-
Brief DescriptionTelocinobufagin is the major endogenous digitalis-like factor.
-
DescriptionTelocinobufagin is the major endogenous digitalis-like factor. Telocinobufagin significantly decreases the bacterial burdens in the spleen and prolongs the survival time of FIST-immunized mice challenged with live S. typhimurium. Telocinobufagin has immunomodulatory activity, can enhance a Th1 immune response to control intracellular infections, could be developed as a novel immunotherapeutic agent to treat cancer and other immune-mediated diseases.
-
In Vitro——
-
In Vivo——
-
SynonymsTelobufotoxin | Telocinobufogenin
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number472-26-4
-
Formula Weight402.53
-
Molecular FormulaC24H34O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (124.22 mM)
-
SMILESCC12CCC(CC1(CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
HJC0197
HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 is an effective exchange protein. Which straightly activated by cAMP (Epac) antagonist (IC50=5.9 μM for Epac2).
-
UUN44923
UUN44923 is a FTO inhibitor.?It may be useful for treating diseases assocd.?with FTO targets, obesity, metabolic syndrome (MS) , type 2 diabetes (T2D) , Alzheimer's diseases, breast cancers, small- cell lung cancers, a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma and the like.?
-
γ-1-MSH, amide
Gamma-MSH (Melanocyte Stimulating Hormone), a putative hormone in the N-terminal region of the ACTH/beta- endorphin (beta-EP) precursor protein, was studied by RIA with an antiserum against gamma 3-MSH in ACTH-producing mouse pituitary tumor cells, AtT-20/D16v.
